Regeneron报告,尽管主要投资者Invesco减少了持有量,但收入仍然很高。 Regeneron reports strong earnings despite major investor Invesco reducing holdings.

Regenenron制药公司在Q4中出现了混合投资活动,Invesco有限公司将其持有量减少了25.6%,Peapack Gladstone金融公司将其地位提高了26.3%。 Regeneron Pharmaceuticals saw mixed investment activity in Q4, with Invesco Ltd. reducing its holdings by 25.6% and Peapack Gladstone Financial Corp increasing its position by 26.3%. 尽管Invesco出售,Regeneron报告收入丰厚,超过12.07 EPS的估算值。 Despite Invesco's sell-off, Regeneron reported strong earnings, exceeding estimates with a $12.07 EPS. 分析家预测,本财政年度该公司将维持35.92 EPS, 股票的“机动购买”评级一致,目标价格为966.88美元。 Analysts predict the company will post 35.92 EPS for the current fiscal year, and the stock has a consensus "Moderate Buy" rating with a target price of $966.88.